Clinical Trials Browser

Phase 2 × Urogenital Neoplasms × Nivolumab × Clear all

NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Phase 2 Active not recruiting

100 enrolled

EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

NCT06237920 2025-09-03

TURANDORELA

Phase 2 Recruiting

90 enrolled

Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT05150236 2023-12-15

ANZUP2001

Phase 2 Unknown

93 enrolled

Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms